Home
All Journals
Expert Opinion on Investigational Drugs
List of Issues
Volume 22, Issue 6

Expert Opinion on Investigational Drugs

Search in:

Advanced search Citation search

Citation search

Ready to submit?
Start a new submission or continue a submission in progress
Go to submission site
Instructions for authors
Editorial policies
Editing services site

Journal metrics
Aims & scope
Journal information
Editorial board
News & calls for papers
Advertising information

Latest articles
Current issue
All volumes & issues
Special issues
Open access articles
Most read articles
Most cited articles

New content alerts
RSS

Subscription options & pricing

Buy a subscription

Your download is now in progress and you may close this window

Did you know that with a free Taylor & Francis Online account you can gain access to the following benefits?

Choose new content alerts to be informed about new research of interest to you
Easy remote access to your institution's subscriptions on any device, from any location
Save your searches and schedule alerts to send you new results
Export your search results into a .csv file to support your research

Have an account?
Login now Don't have an account?
Register for free

Login or register to access this feature

Have an account?
Login now Don't have an account?
Register for free

Choose new content alerts to be informed about new research of interest to you
Easy remote access to your institution's subscriptions on any device, from any location
Save your searches and schedule alerts to send you new results
Export your search results into a .csv file to support your research

Expert Opinion on Investigational Drugs, Volume 22, Issue 6 (2013)

Browse this journal

Latest articles
Current issue
List of issues
Special issues
Open access articles
Most read articles
Most cited articles

Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days

Expert Opinion on Investigational Drugs, Volume 22, Issue 6 (2013)

See all volumes and issues

Vol 33, 2024 Vol 32, 2023 Vol 31, 2022 Vol 30, 2021 Vol 29, 2020 Vol 28, 2019 Vol 27, 2018 Vol 26, 2017 Vol 25, 2016 Vol 24, 2015 Vol 23, 2014 Volume 22, 2013 Vol 21, 2012 Vol 20, 2011 Vol 19, 2010 Vol 18, 2009 Vol 17, 2008 Vol 16, 2007 Vol 15, 2006 Vol 14, 2005 Vol 13, 2004 Vol 12, 2003 Vol 11, 2002 Vol 10, 2001 Vol 9, 2000 Vol 8, 1999 Vol 7, 1998 Vol 6, 1997 Vol 5, 1996 Vol 4, 1995 Vol 3, 1994

Select to download all citations or PDFs

Download citations Download PDFs Download issue

Browse by section (All)

Display order (Default)
Published online date
Page number
Section A-Z
Most read
Most cited

Editorial

Protein kinase inhibitors: breakthrough medicines and the next generation

Tomi K Sawyer, Joe C Wu, Jonathon R Sawyer & Jessie M English

Pages: 675-678

Published online: 25 May 2013

AbstractforProtein kinase inhibitors: breakthrough medicines and the next generation | Full Text | References | PDF (220.4 KB)

2022 Views
7 CrossRef citations
0Altmetric

Free Access

Editorial

Overcoming resistance to mTOR inhibition for enhanced strategies in clinical trials

Aung Naing MD FACP

Pages: 679-685

Published online: 30 Apr 2013

First Page PreviewforOvercoming resistance to mTOR inhibition for enhanced strategies in clinical trials | Full Text | References | PDF (336.9 KB)

900 Views
7 CrossRef citations
0Altmetric

Free Access

Reviews

Review Article

Investigational Janus kinase inhibitors

Constantine S Tam MBBS MD & Srdan Verstovsek MD PhD

Pages: 687-699

Published online: 23 Feb 2013

AbstractforInvestigational Janus kinase inhibitors | Full Text | References | PDF (492.6 KB)

1042 Views
43 CrossRef citations
0Altmetric

Article

Therapeutic potential of serum and glucocorticoid inducible kinase inhibition

Florian Lang & Jakob Voelkl

Pages: 701-714

Published online: 19 Mar 2013

AbstractforTherapeutic potential of serum and glucocorticoid inducible kinase inhibition | Full Text | References | PDF (559 KB)

1142 Views
70 CrossRef citations
0Altmetric

Review Article

Next generation of mammalian target of rapamycin inhibitors for the treatment of cancer

Valerie Nelson, Jessica K Altman & Leonidas C Platanias

Pages: 715-722

Published online: 02 Apr 2013

AbstractforNext generation of mammalian target of rapamycin inhibitors for the treatment of cancer | Full Text | References | PDF (316.5 KB)

376 Views
17 CrossRef citations
0Altmetric

Review Article

Cyclin-dependent kinase inhibitor therapy for hematologic malignancies

Prithviraj Bose, Gary L Simmons & Steven Grant

Pages: 723-738

Published online: 06 May 2013

AbstractforCyclin-dependent kinase inhibitor therapy for hematologic malignancies | Full Text | References | PDF (387.2 KB)

1039 Views
111 CrossRef citations
0Altmetric

Review Article

Phase I/II RAF kinase inhibitors in cancer therapy

Samra Turajlic, Zohra Ali, Nadia Yousaf & James Larkin

Pages: 739-749

Published online: 06 May 2013

AbstractforPhase I/II RAF kinase inhibitors in cancer therapy | Full Text | References | PDF (346.6 KB)

436 Views
10 CrossRef citations
0Altmetric

Review Article

Tyrosine kinase inhibitors as novel drugs for the treatment of diabetes

Patricia O Prada & Mario JA Saad

Pages: 751-763

Published online: 25 May 2013

AbstractforTyrosine kinase inhibitors as novel drugs for the treatment of diabetes | Full Text | References | PDF (676.9 KB)

594 Views
25 CrossRef citations
0Altmetric

Drug Evaluations

Article

Axitinib for the treatment of advanced non-small-cell lung cancer

Judy W King MRCP PhD & Siow-Ming Lee FRCP PhD

Pages: 765-773

Published online: 01 Mar 2013

Abstractfor Axitinib for the treatment of advanced non-small-cell lung cancer | Full Text | References | PDF (255.1 KB)

376 Views
10 CrossRef citations
0Altmetric

Article

Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib

Enrico Derenzini MD & Anas Younes MD

Pages: 775-785

Published online: 26 Feb 2013

AbstractforTargeting the JAK-STAT pathway in lymphoma: a focus on pacritinib | Full Text | References | PDF (611.3 KB)

983 Views
29 CrossRef citations
0Altmetric

Review Article

Imatinib and prostate cancer: lessons learned from targeting the platelet-derived growth factor receptor

Aaron Rosenberg MD & Paul Mathew MD

Pages: 787-794

Published online: 01 Apr 2013

Abstractfor Imatinib and prostate cancer: lessons learned from targeting the platelet-derived growth factor receptor | Full Text | References | PDF (309.2 KB)

456 Views
28 CrossRef citations
0Altmetric

Review Article

Dasatinib: a novel therapy for breast cancer?

Kevin S Scher MD MBA & George Somlo MD

Pages: 795-801

Published online: 18 Apr 2013

Abstractfor Dasatinib: a novel therapy for breast cancer? | Full Text | References | PDF (226.4 KB)

404 Views
8 CrossRef citations
0Altmetric

Research Article

Article

Page: i

Published online: 25 May 2013

368 Views
0 CrossRef citations
0Altmetric

Free Access

Explore articles

Latest
Open access
Most read
Most cited
Trending

Explore the most recently published articles

Investigational drugs for the treatment of acromegaly: new agents to transform therapy

Rosa Pirchio et al.

Review Article | Published online: 30 Apr 2024

Safety, tolerability, and pharmacokinetics of the novel RdRp inhibitor SHEN26 against SARS-CoV-2: a randomized, placebo-controlled, double-blind Phase I study in healthy subjects

Cheng Sun et al.

Article | Published online: 30 Apr 2024

Frontotemporal dementia: from genetics to therapeutic approaches

Francesca R. Buccellato et al.

Review Article | Published online: 30 Apr 2024

Open Access

Drugs in preclinical and early clinical development for the treatment of chagas disease: the current status

Fernanda Karoline Vieira da Silva Torchelsen et al.

Review Article | Published online: 30 Apr 2024

View all latest articles

Download citations

Choose format

RIS (ProCit, Reference Manager)
BibTeX
RefWorks Direct Export

Download citations

Expert Opinion on Investigational Drugs (Vol.22, Iss.6, 2013)

Access Rights

Only articles that you have access rights to view will be downloaded. The green tick (full access) and orange padlock (open access) icons indicate that you have full access.

Do you want to proceed?